September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Long-term outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
Author Affiliations & Notes
  • Lea Querques
    Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele , Milan, Italy
  • Francesco Bandello
    Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele , Milan, Italy
  • Federico Corvi
    Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele , Milan, Italy
  • Carlo La Spina
    Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele , Milan, Italy
  • Lucia Benatti
    Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele , Milan, Italy
  • David Sarraf
    Stein Eye Institute, Los Angeles, California, United States
  • K Bailey Freund
    Vitreous Retina Macula Consultants of New York, New York, New York, United States
  • Maurizio Battaglia Parodi
    Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele , Milan, Italy
  • Eric H Souied
    University Paris Est Creteil, Creteil, France
  • Giuseppe Querques
    Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele , Milan, Italy
  • Footnotes
    Commercial Relationships   Lea Querques, None; Francesco Bandello, Allergan (C), Bayer (C), Novartis (C); Federico Corvi, None; Carlo La Spina, None; Lucia Benatti, None; David Sarraf, Genentech (C), Regeneron (C); K Bailey Freund, Genentech (C), Regeneron (C); Maurizio Battaglia Parodi, Allergan (C), Bayer (C), Novartis (C); Eric Souied, Allergan (C), Bayer (C), Novartis (C); Giuseppe Querques, Allergan (C), Bayer (C), Novartis (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 541. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Lea Querques, Francesco Bandello, Federico Corvi, Carlo La Spina, Lucia Benatti, David Sarraf, K Bailey Freund, Maurizio Battaglia Parodi, Eric H Souied, Giuseppe Querques; Long-term outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):541.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the long-term outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration (AMD) and diabetic retinopathy (DR).

Methods : Patients from 4 high-volume referral centers who presented with concomitant neovascular AMD and DR, and received intravitreal anti-VEGF therapy, were retrospectively enrolled into this study. Data retrieved from medical records and multi-modal imaging were analyzed.

Results : Forty-one eyes of 38 patients (21 male, 17 female; mean age 78±8 years) were enrolled. Median follow up was 28±19 [12-72] months. During follow-up, a mean of 9.2±7.4 intravitreal anti-VEGF injections per eye were administrated: 13 eyes (32%) received a mean of 5.7±3.7injections of bevacizumab, 35 eyes (85%) received a mean of 6.6±4.3 injections of ranibizumab, 1 eye (2%) received 7 injections of pegaptanib, and 8 eyes (20%) received a mean of 6.1±5.5 injections of aflibercept. Best-corrected visual acuity was 0.5±0.3 LogMAR at baseline; it improved significatively at 1 year (0.3±0.3 LogMAR; p=0.02) and returned to baseline values at last follow up visit (0.6±0.4 LogMAR; p=0.26). Mean central macular thickness (CMT) significantly decreased from 408±150 μm at baseline to 328±104 μm at one year (p=0.021) and to 335±127 μm at last follow up visit (p=0.032). No adverse events were recorded. The baseline severity of DR (International Clinical Diabetic Retinopathy Disease Severity Scale) was graded as mild non proliferative diabetic retinopathy (NPDR) in 21 (51%) eyes, moderate NPDR in 15 (36%) eyes, severe NPDR in 3 (7%) eyes, and proliferative diabetic retinopathy (PDR), but inactive due to panretinal photocoagulation, in 2 (5%) eyes; at last follow-up visit, 1 eye graded as moderate NPDR at baseline improved to mild, 1 eye graded as severe NPDR at baseline improved to mild and one eye graded as severe NPDR was inactivated due to photocoagulation

Conclusions : Long-term analysis of intravitreal anti-VEGF therapy for eyes with both neovascular AMD and DR showed stabilization of BCVA and a reduction in CMT, along with stable or improved DR throughout follow-up.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×